Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Update

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the target of a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 101,823 shares, a drop of 34.1% from the December 31st total of 154,542 shares. Based on an average daily trading volume, of 75,470 shares, the short-interest ratio is presently 1.3 days. Approximately 1.5% of the company’s stock are short sold. Approximately 1.5% of the company’s stock are short sold. Based on an average daily trading volume, of 75,470 shares, the short-interest ratio is presently 1.3 days.

Calidi Biotherapeutics Trading Down 2.9%

Shares of CLDI stock traded down $0.03 during mid-day trading on Friday, reaching $1.02. 89,792 shares of the company’s stock traded hands, compared to its average volume of 74,493. The company has a current ratio of 2.12, a quick ratio of 2.12 and a debt-to-equity ratio of 0.11. The firm has a 50 day moving average price of $1.25 and a two-hundred day moving average price of $2.35. Calidi Biotherapeutics has a 12 month low of $0.97 and a 12 month high of $19.20.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($2.21) earnings per share (EPS) for the quarter. Equities analysts forecast that Calidi Biotherapeutics will post -4.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Calidi Biotherapeutics

A hedge fund recently bought a new stake in Calidi Biotherapeutics stock. Warberg Asset Management LLC purchased a new position in shares of Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 18,705 shares of the company’s stock, valued at approximately $28,000. Warberg Asset Management LLC owned 0.55% of Calidi Biotherapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.